Jennison Associates LLC purchased a new position in Sanofi (NASDAQ:SNY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 159,507 shares of the company's stock, valued at approximately $7,932,000.
Other hedge funds have also recently made changes to their positions in the company. IFP Advisors Inc lifted its position in Sanofi by 68.3% in the 3rd quarter. IFP Advisors Inc now owns 2,820 shares of the company's stock valued at $151,000 after acquiring an additional 1,144 shares in the last quarter. Koshinski Asset Management Inc. purchased a new stake in shares of Sanofi in the 3rd quarter worth $203,000. UMB Bank n.a. increased its stake in shares of Sanofi by 38.8% in the 3rd quarter. UMB Bank n.a. now owns 1,876 shares of the company's stock worth $101,000 after purchasing an additional 524 shares in the last quarter. Simplicity Solutions LLC increased its stake in shares of Sanofi by 2.5% in the 3rd quarter. Simplicity Solutions LLC now owns 75,440 shares of the company's stock worth $4,047,000 after purchasing an additional 1,848 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC increased its stake in shares of Sanofi by 18.4% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 8,795 shares of the company's stock worth $472,000 after purchasing an additional 1,368 shares in the last quarter. 10.04% of the stock is owned by institutional investors.
Sanofi Stock Down 0.5 %
SNY traded down $0.23 during trading on Friday, hitting $49.13. The stock had a trading volume of 4,148,180 shares, compared to its average volume of 2,214,580. The company has a market capitalization of $124.28 billion, a PE ratio of 24.69, a PEG ratio of 1.49 and a beta of 0.61. Sanofi has a twelve month low of $42.63 and a twelve month high of $56.26. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The stock has a 50 day simple moving average of $47.71 and a two-hundred day simple moving average of $48.37.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. On average, research analysts predict that Sanofi will post 4.09 earnings per share for the current year.
Sanofi Increases Dividend
The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a dividend of $1.478 per share. This is an increase from Sanofi's previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi's payout ratio is presently 69.35%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on SNY shares. Morgan Stanley started coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an "equal weight" rating and a $55.00 price target for the company. TheStreet lowered Sanofi from a "b" rating to a "c" rating in a research note on Friday, February 9th. Finally, StockNews.com lowered Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $55.00.
View Our Latest Stock Report on Sanofi
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
